Abstract:Abstract Melanoma has seen a remarkable improvement in the treatment of advanced disease. However, the majority of patients still relapse with the emergence of resistant disease. This is especially true for BRAF inhibitors, were multiple mechanisms of resistance have been uncovered. However, the lack of dependable models to develop approaches to overcome resistance, poses a real challenge for clinical decisions on second line therapies. In addition, combination therapies necessary to achieve long term responses increase the number of possibilities to be assessed. In this study, we developed patient derived xenograft (PDX) models from BRAF inhibitor resistant patients and, after characterization, tested rational second line combination therapies in co-clinical trials.Fresh tumor tissue from 12 patients after progression on vemurafenib or dabrafenib was implanted into immune deficient NSG mice. Once the tumor grafts were established, mice were continually dosed with PLX4720 to approximate clinical plasma levels to preserve the resistant phenotype. Xenografts were then characterized for genomic alterations and pathway activation status using a targeted sequencing array and a reverse phase protein array, respectively. We found at least 2 and up to 9 known deleterious alterations in all samples, many of which have been described as conferring resistance. The protein array clustered into two major groups: MAPK pathway activated and PI3K pathway activated, again consistent with previous reports. Integrating these data allowed us to design rational combination therapies for in vivo testing. We treated a PDX model with MET amplification and high phospho c-Met with the BRAF inhibitor LGX818 20mg/kg QD, the MEK inhibitor MEK162 3mg/kg QD, and the c-Met inhibitor INC280 25mg/kg QD (all p.o.). Although INC280 alone led to significant decrease in tumor growth, only the LGX818/ MEK162/ INC280 triple combination led to complete and sustained tumor regression in all mice. Further, we tested a second PDX model with a MET amplification (albeit broader and lower) but baseline pMET on the protein level. In this model, INC280 did not show any antitumor effect confirming the specificity for c-Met and the importance of validating genomic data.In summary, using our BRAF inhibitor resistant PDX model pipeline we were not only able to identify actionable alterations in all models, but also to test rational second line combination therapies in pre-clinical in vivo trials. Genomic data alone might not be sufficient to accurately predict therapy responses and protein arrays were a valuable tool to validate deleterious alteration calls. This study represents an important step towards improving personalized medicine in melanoma, and highlights the potential use of c-Met inhibitors in melanoma combination therapy in a defined subset of patients. Citation Format: Clemens Krepler, Min Xiao, Katrin Sproesser, Patricia Brafford, Batool Shannan, Marilda Beqiri, Wei Xu, Bradley Garman, Katherine L. Nathanson, Xiaowei Xu, Giorgos Karakousis, Gordon B. Mills, Yiling Lu, Giordano Caponigro, Markus Boehm, Malte Peters, Lynn Schuchter, Meenhard Herlyn. Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models of melanoma identify c-Met as an effective second line combination therapy target. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2842. doi:10.1158/1538-7445.AM2015-2842

Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

Mir‐200c/bmi1 Axis and Epithelial–mesenchymal Transition Contribute to Acquired Resistance to BRAF Inhibitor Treatment

Inhibition of the Rho/MRTF pathway improves the response of BRAF‐resistant melanoma to PD1/PDL1 blockade

Data from BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells

141 Targeting TGFβ Signaling in BRAF Mutant Melanoma

Dual MAPK Inhibition Triggers Pro-inflammatory Signals and Sensitizes BRAF V600E Glioma to T Cell-Mediated Checkpoint Therapy

Abstract 4747: Novel targets for BRAF V600E and BRAF V600E RAC1P29S drug resistant melanoma

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.

A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

Dual VEGFA/BRAF targeting boosts PD‐1 blockade in melanoma through GM‐CSF‐mediated infiltration of M1 macrophages

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma

Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells

BRAF Peptide Vaccine Facilitates Therapy of Murine BRAF-mutant Melanoma

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

Cnsc-25. Concurrent Immune Checkpoint Blockade Enhances The Survival Benefit Of Clinically Relevant Mapk Pathway Inhibitors In A T Cell-Dependent Manner

Abstract 2842: Personalized Pre-Clinical Trials in BRAF Inhibitor Resistant Patient Derived Xenograft Models of Melanoma Identify C-Met As an Effective Second Line Combination Therapy Target

Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma

Mutation-Specific CRISPR Targeting with SaCas9 and AsCas12a Restores Therapeutic Sensitivity in Treatment-Resistant Melanoma